Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, Hims & Hers Health
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.
Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.
Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo Nordisk’s diabetes drug as soon as 2025.It reported strong quarterly earnings. The stock rose 8.
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025. "We have already confirmed a core supplier for this addition and over the next few months expect to finish completing test and batch validation,
8h
Hims & Hers stock could dive soon despite strong results
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
1d
on MSN
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
12h
Hims & Hers Health: Another Blowout Quarter Ignored
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
10h
Hims & Hers price target raised to $21 from $18 at Piper Sandler
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
bovnews
1d
HIMS Stock Fluctuations: The Real Story
On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $20.36 which represents a slight increase of $1.53 or 8.13% from the prior close of $18.83. The stock opened at ...
Seeking Alpha
1d
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Hims
& Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
1d
Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details
Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...
10h
Seaport Global Sticks to Their Buy Rating for Hims & Hers Health (HIMS)
Seaport Global analyst Aaron Kessler maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price ...
Yahoo Finance
20h
HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts
Hims
& Hers Health, Inc.
HIMS
delivered an earnings per share (EPS) of 32 cents in third-quarter 2024 against the ...
1d
Palantir, Trump Media, Hims & Hers Health, NXP Semiconductors, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow ...
Investor's Business Daily on MSN
6h
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
Hims stock rose early Tuesday after compounded weight-loss drugs helped build on a "robust" trajectory for Hims & Hers Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
New York Stock Exchange
Hers
Trade
Liraglutide
Ozempic
Feedback